Cognition Therapeutics CFO buys 10,000 shares
Cognition Therapeutics Chief Financial Officer John Brendan Doyle bought 10,000 shares of common stock in an open-market purchase at $1.13 per share.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Cognition Therapeutics Chief Financial Officer John Brendan Doyle bought 10,000 shares of common stock in an open-market purchase at $1.13 per share. The transaction involved directly held shares. Following this purchase, Doyle directly owns a total of 627,509 shares of Cognition Therapeutics common stock.
Insider Trade Summary
Net Buyer: 10,000 shares
Net Buy
1 txn
Insider
Doyle John Brendan
Role
Chief Financial Officer
Bought
10,000 shs ($11K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 10,000 | $1.13 | $11K |
Holdings After Transaction:
Common Stock — 627,509 shares (Direct)
Key Figures
Shares purchased: 10,000 shares
Purchase price: $1.13 per share
Shares owned after transaction: 627,509 shares
+1 more
4 metrics
Shares purchased
10,000 shares
Open-market purchase of common stock on April 16, 2026
Purchase price
$1.13 per share
Price paid for Cognition Therapeutics common stock
Shares owned after transaction
627,509 shares
Direct holdings of CFO John Brendan Doyle following the purchase
Net share change
10,000 shares
Net buy shares for this Form 4 transaction
Key Terms
open-market purchase, Common Stock, Form 4, Chief Financial Officer
4 terms
open-market purchase financial
"described as an open-market purchase at $1.13 per share"
An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.
Common Stock financial
"security_title is reported as Common Stock in the transaction"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
Form 4 regulatory
"This transaction is disclosed in a Form 4 insider filing"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
Chief Financial Officer financial
"John Brendan Doyle serves as Chief Financial Officer"
A Chief Financial Officer (CFO) is the person in charge of a company's money and financial planning. They decide how to spend, save, and invest funds to help the company grow and stay stable. Their role is important because good financial decisions keep the company healthy and successful.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Cognition Therapeutics (CGTX) report for John Brendan Doyle?
Cognition Therapeutics reported that Chief Financial Officer John Brendan Doyle executed an open-market purchase of 10,000 shares of common stock at $1.13 per share. This transaction is disclosed in a Form 4 insider filing for transparency regarding executive share ownership.
What are John Brendan Doyle’s Cognition Therapeutics (CGTX) holdings after this Form 4 trade?
After the reported transaction, John Brendan Doyle directly holds 627,509 shares of Cognition Therapeutics common stock. This total reflects his position immediately following the 10,000-share open-market purchase disclosed in the Form 4 filing.
What does transaction code P mean in the Cognition Therapeutics (CGTX) Form 4?
Transaction code P in the Cognition Therapeutics Form 4 indicates a purchase in an open market or private transaction. In this case, it records the CFO’s acquisition of 10,000 common shares at $1.13 per share as a straightforward buy of non-derivative stock.
Was the Cognition Therapeutics (CGTX) insider trade a derivative or common stock transaction?
The insider trade was in Cognition Therapeutics common stock, categorized as a non-derivative security. The Form 4 reports the CFO’s open-market purchase of 10,000 common shares at $1.13 each, with no associated options, warrants, or other derivative instruments in this transaction.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates